Zhou Yan, Zeng Cheng, Li Xin, Wu Pei-Li, Yin Ling, Yu Xiao-Lan, Zhou Ying-Fang, Xue Qing
Department of Obstetrics and Gynecology, Peking University First Hospital, No. 1 Xi'anmen Street, 100034, Beijing, China.
J Mol Med (Berl). 2016 Aug;94(8):887-97. doi: 10.1007/s00109-016-1396-1. Epub 2016 Feb 22.
Estrogen receptor beta (ERβ, encoded by ESR2 gene) and cytochrome P450 aromatase (encoded by CYP19A1 gene) play critical roles in endometriosis, and the levels of insulin-like growth factor-I (IGF-I) in the peritoneal fluid are significantly higher in patients with endometriosis compared with those in normal women. However, the effects and mechanisms of IGF-I on ERβ and aromatase expression remain to be fully elucidated. In this study, human endometriotic stromal cells (ESCs) and endometrial cells (EMs) derived from ovarian endometriomas and eutopic endometrial tissues. ESCs were cultured with IGF-I, signal pathway inhibitors, and siRNAs. ERβ and aromatase expression were measured by real-time PCR and Western, respectively. The binding of c-Jun and CREB to the ESR2 and CYP19A1 promoters was assessed by chromatin immunoprecipitation assay. Animal experiments were performed in a xenograft mouse model. Levels of IGF-I mRNA in ESCs were markedly higher than those in EMs. IGF-I upregulated ERβ and aromatase expression in ESCs after stimulation of the IGF1R/PI3K/AKT pathway. Following IGF-I treatment, a marked increase in c-Jun and CREB phosphorylation occurred, enhancing binding to the ESR2 and CYP19A1 promoters. An IGF1R inhibitor in vivo reduced IGF-I-induced endometriosis graft growth and ERβ and aromatase expression. In conclusion, this is the first report to describe a mechanistic analysis of ERβ and aromatase expression regulated by IGF-I in ESCs. Moreover, an IGF1R inhibitor impeded ectopic lesion growth in nude mice. These findings suggest that an inhibitor of IGF1R might have therapeutic potential as an antiendometriotic drug.
Level of IGF-I mRNA in ESCs is markedly higher than that in EMs. IGF-I up-regulates ERβ and aromatase expression via IGF1R/PI3K/AKT pathway. C-Jun and CREB are recruited to ESR2 or CYP19A1 promoter by IGF-I stimulation. IGF-1R inhibitors in vivo impede the growth of ectopic lesions in nude mice.
雌激素受体β(ERβ,由ESR2基因编码)和细胞色素P450芳香化酶(由CYP19A1基因编码)在子宫内膜异位症中起关键作用,与正常女性相比,子宫内膜异位症患者腹腔液中胰岛素样生长因子-I(IGF-I)水平显著更高。然而,IGF-I对ERβ和芳香化酶表达的影响及机制仍有待充分阐明。在本研究中,从卵巢子宫内膜异位囊肿和在位子宫内膜组织中获取人子宫内膜异位症间质细胞(ESC)和子宫内膜细胞(EM)。将ESC与IGF-I、信号通路抑制剂和小干扰RNA(siRNA)一起培养。分别通过实时聚合酶链反应(PCR)和蛋白质免疫印迹法检测ERβ和芳香化酶的表达。通过染色质免疫沉淀试验评估c-Jun和环磷腺苷效应元件结合蛋白(CREB)与ESR2和CYP19A1启动子的结合。在异种移植小鼠模型中进行动物实验。ESC中IGF-I信使核糖核酸(mRNA)水平明显高于EM。IGF-I在刺激胰岛素样生长因子1受体(IGF1R)/磷脂酰肌醇-3激酶(PI3K)/蛋白激酶B(AKT)信号通路后上调ESC中ERβ和芳香化酶的表达。IGF-I处理后,c-Jun和CREB磷酸化显著增加,增强了与ESR2和CYP19A1启动子的结合。体内IGF1R抑制剂减少了IGF-I诱导的子宫内膜异位症移植物生长以及ERβ和芳香化酶的表达。总之,这是首篇描述IGF-I调控ESC中ERβ和芳香化酶表达机制分析的报告。此外,IGF1R抑制剂阻碍了裸鼠异位病变的生长。这些发现表明,IGF1R抑制剂作为一种抗子宫内膜异位症药物可能具有治疗潜力。
ESC中IGF-I mRNA水平明显高于EM。IGF-I通过IGF1R/PI3K/AKT信号通路上调ERβ和芳香化酶表达。IGF-I刺激后,c-Jun和CREB被募集至ESR2或CYP19A1启动子。体内IGF-1R抑制剂阻碍裸鼠异位病变生长。